Abstract
Customized chemotherapy is increasingly used in the management of patients with advanced non-small cell lung cancer (NSCLC). However, the most reliable methodology to determine biomarker status is neither fully elucidated nor agreed upon. Accordingly, we evaluated the predictive efficiency of qRT-PCR and immunohistochemical analysis (IHC) on excision cross complementation group 1 (ERCC1), breast cancer susceptibility gene 1 (BRCA1), ribonucleotide reductase subunit M1 (RRM1) and class III ß-tubulin (TUBB3).
Originalsprog | Engelsk |
---|---|
Tidsskrift | Lung Cancer |
Vol/bind | 75 |
Udgave nummer | 3 |
Sider (fra-til) | 306-12 |
Antal sider | 7 |
ISSN | 0169-5002 |
DOI | |
Status | Udgivet - 2012 |